New Results from Second Phase 3 Study Show Significant Efficacy of Guselkumab and Superiority Versus Humira® in Treatment of Moderate to Severe Plaque Psoriasis

Dermatology March 6, 2017 at 8:58 AM 0 comments

Additional Phase 3 Study Data Show Significant Efficacy of Guselkumab in Patients Experiencing Inadequate Response to STELARA® in the Treatment of Moderate to Severe Plaque Psoriasis. Orlando, Florida, 3 March, 2017 ― Janssen Research & Development, LLC (Janssen) announced today new findings from two pivotal Phase 3 studies reporting theRead More

Clinical and Preclinical Data on Monalizumab to Be Presented at Aacr Annual Meeting 2017

Uncategorized March 3, 2017 at 8:58 AM 0 comments

Reinforcing safety profile of monalizumab and rationale for broad ability to combine with other anticancer agents. Marseille, France, March 2, 2017 – Innate Pharma SA (the “Company” – Euronext Paris: FR0010331421 – IPH) today announces that data on monalizumab will be presented at the American Association for Cancer Research (AACR)Read More

Introducing the European Medical Journal 2.1

Introducing the European Medical Journal 2.1

European Medical Journal March 2, 2017 at 8:44 AM 0 comments

United Kingdom, March 2, 2017: A warm welcome to the year’s first issue of the flagship eJournal, the European Medical Journal. Contained within is a collection of peer-reviewed articles plucked from a plethora of therapeutic areas, aiming to facilitate an interdisciplinary transfer of knowledge and to promote a holistic medicalRead More

Positive Results for Relvar® Ellipta® Lung Function Study in Patients with Well-Controlled Asthma

Respiratory February 23, 2017 at 3:19 PM 0 comments

GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive headline results from a non-inferiority lung function study, which demonstrated that patients with well-controlled asthma were able to switch to the once-daily Relvar® Ellipta® (fluticasone furoate/vilanterol, FF/VI) 100/25, an inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) combination, from the twice-dailyRead More

Philips Reinforces Leadership in Image-Guided Therapy Solutions with Global Launch of next Generation Azurion Platform

Philips Reinforces Leadership in Image-Guided Therapy Solutions with Global Launch of next Generation Azurion Platform

Uncategorized February 23, 2017 at 3:03 PM 0 comments

Developed in collaboration with leading hospitals worldwide, Philips Azurion is an innovative image-guided therapy platform that allows clinicians to easily and confidently perform a wide range of routine and complex procedures, helping them to optimize interventional lab performance and provide superior care Azurion is powered by ConnectOS, Philips’ newly developed operating system toRead More

Janssen Presents Newly-Published Data on the Use of ZYTIGA® (Abiraterone Acetate) Plus Prednisone in the Real-World, Outside the Clinical Trial Setting

Urology February 17, 2017 at 2:56 PM 0 comments

Janssen Presents Newly-Published Data on the Use of ZYTIGA® (Abiraterone Acetate) Plus Prednisone in the Real-World, Outside the Clinical Trial Setting1 Beerse, Belgium, February 17, 2017 – Janssen-Cilag International NV today announced the publication of data revealing radiographic progression-free survival (rPFS) of 16.5 months (95% CI, 13.5–20.0) and treatment durationRead More

New Data Shows Stelara® (Ustekinumab) Maintained Clinical Response and Remission After Two Years of Treatment in Patients with Moderate to Severe Crohn’s Disease

Gastroenterology February 17, 2017 at 2:22 PM 0 comments

Results of the IM-UNITI Study Presented at the 12th Congress of ECCO Barcelona, Spain, February 17, 2017 – Janssen-Cilag International NV (“Janssen”) announced today new two-year data from the ongoing IM-UNITI long-term extension (LTE) study evaluating the efficacy and safety of subcutaneous (SC) STELARA® (ustekinumab) in patients with moderate toRead More

Polyganics’ “STOP NEUROMA” Study Interim Data Shows Reduction in Pain

Uncategorized February 16, 2017 at 10:20 AM 0 comments

NEUROCAP® 3-month interim data show an average pain reduction of 84% Final patient recruited in “STOP NEUROMA” clinical study, full data due to be reported by Q3 2018. Groningen, The Netherlands, February 16, 2017 – Polyganics, a privately held medical technology company, announced today that interim results show a sharp improvementRead More

BIAL and Neurocrine Announce Exclusive North American Licensing Agreement for Opicapone

Uncategorized February 10, 2017 at 2:28 PM 0 comments

ONGENTYS®(opicapone) Approved in Europe in June 2016 Porto, Portugal and San Diego, California, February 10, 2017 – BIAL and Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that they have entered into an exclusive licensing agreement for the development and commercialization of opicapone in North America. ONGENTYS® (opicapone) is a once-daily,Read More

Juntendo University Research: Brain Imaging and Causal Assessment of Impairments Reveals Metamemory Regions

Juntendo University Research: Brain Imaging and Causal Assessment of Impairments Reveals Metamemory Regions

Neurology January 18, 2017 at 2:43 PM 0 comments

Tokyo, January 18, 2017 – Juntendo University researchers identify areas of the brain responsible for metacognitive memory evaluation in macaque monkeys. “We know how confidently we know,” explains Yasushi Miyashita and colleagues at Juntendo University Graduate School of Medicine and the University of Tokyo School of Medicine in their recent report.Read More